CoChat

Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis

Open access
Bao, Xuanwen, Li, Qiong, Chen, Jinzhang, Chen, Diyu, Ye, Chanqi, Dai, Xiaomeng, Wang, Yanfang, Li, Xin, Rong, Xiaoxiang, Cheng, Fei, Jiang, Ming, Zhu, Zheng, Ding, Yongfeng, Sun, Rui, Liu, Chuan, Huang, Lingling, Jin, Yuzhi, Li, Bin, Lu, Juan, Wu, Wei, Guo, Yixuan, Fu, Wenguang, Langley, Sarah Raye, Tano, Vincent, Fang, Weijia, Guo, Tiannan, Sheng, Jianpeng, Zhao, Peng, Ruan, Jian · 2022 · Cancer Immunology Research
Cited by 80

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a relatively rare but highly aggressive tumor type that responds poorly to chemotherapy and immunotherapy. Comprehensive molecular characterization of ICC is essential for the development of novel therapeutics. Here, we constructed two independent cohorts from two clinic centers. A comprehensive multiomics analysis of ICC via proteomic, whole-exome sequencing (WES), and single-cell RNA sequencing (scRNA-seq) was performed. Novel ICC tumor subtypes were derived in the training cohort (n = 110) using proteomic signatures and their associated activated pathways, which were further validated in a validation cohort (n = 41). Three molecular subtypes, chromatin remodeling, metabolism, and chronic inflammation, with distinct prognoses in ICC were identified. The chronic inflammation subtype was associated with a poor prognosis. Our random forest algorithm revealed that mutation of lysine methyltransferase 2D (KMT2D) frequently occurred in the metabolism subtype and was associated with lower inflammatory activity. scRNA-seq further identified an APOE+C1QB+ macrophage subtype, which showed the capacity to reshape the chronic inflammation subtype and contribute to a poor prognosis in ICC. Altogether, with single-cell transcriptome-assisted multiomics analysis, we identified novel molecular subtypes of ICC and validated APOE+C1QB+ tumor-associated macrophages as potential immunotherapy targets against ICC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-21-1101

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 80

Metadata

Authors
Bao, X., Li, Q., Chen, J., Chen, D., Ye, C., Dai, X., Wang, Y., Li, X., Rong, X., Cheng, F., Jiang, M., Zhu, Z., Ding, Y., Sun, R., Liu, C., Huang, L., Jin, Y., Li, B., Lu, J., Wu, W., Guo, Y., Fu, W., Langley, S. R., Tano, V., Fang, W., Guo, T., Sheng, J., Zhao, P., & Ruan, J.
Venue
Cancer Immunology Research
Published
2022-05-20
Volume
10
Issue
7
Pages
811-828
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W4281389521
Cited by
80
References
16
FWCI
13.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis. https://app.cochat.ai/papers/10.1158/2326-6066.cir-21-1101
The paper
Bao, X., Li, Q., Chen, J., Chen, D., Ye, C., Dai, X., Wang, Y., Li, X., Rong, X., Cheng, F., Jiang, M., Zhu, Z., Ding, Y., Sun, R., Liu, C., Huang, L., Jin, Y., Li, B., Lu, J., . . . Ruan, J. (2022). Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-21-1101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.